Skip to main content
. 2024 Dec 30;24:1585. doi: 10.1186/s12885-024-13377-1

Table 3.

LVEF and GLS of single and dual anti-HER2 targeted therapy group

Trastuzumab
(n = 40)
Trastuzumab
+ pertuzumab
(n = 40)
P value
LVEF (%) 62.0%±5.9% 63.9%±4.9% 0.516
GLS (%) −19.3%±2.8 −19.6%±3.3% 0.632
Abnormal GLS 7 (17.5%) 8 (20%) 0.365